Navigation Links
Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of Clinical Hypertension
Date:9/4/2007

study demonstrated that nebivolol was well tolerated by comparison to placebo treatment. Headache was the most common treatment-related adverse event experienced by 7.1% of the pooled nebivolol-treated patients (dosages of 1.25mg to 40mg once daily) and 7.4% of the placebo-treated patients. Of note, in the pooled nebivolol group, the incidence of AEs commonly associated with traditional beta blocker use, including fatigue (3.6% vs. 2.5% with placebo), erectile dysfunction (0.2%), and depression (0.2%) was low. Moreover, nebivolol was not associated with adverse changes in blood glucose values.

"The publication of nebivolol's first U.S. clinical trial further reinforces its longstanding use in patients worldwide," said Neil Shusterman, M.D., Senior Vice President, Clinical Development, Forest Research Institute. "The majority of Americans afflicted with this disease are still not controlled, so clearly there is a need for more treatment options. This study showed that nebivolol significantly lowered blood pressure in patients with mild-to-moderate hypertension and we anticipate it will be an important therapy for physicians."

About Hypertension

Hypertension, also known as high blood pressure, affects approximately 72 million people in the U.S. and 65 percent of patients diagnosed with hypertension have not reduced their blood pressure to an acceptable range. If left untreated, hypertension can eventually damage important organs such as the heart, brain, eyes or kidneys. High blood pressure greatly increases the risk of certain health problems such as stroke, heart attack, and kidney failure.

About Nebivolol

Nebivolol is a selective beta 1-blocker with vasodilating properties and is already approved and successfully marketed for the treatment of hypertension in more than 50 countries outside of North America.

About Forest Laboratories and Its Products

Forest Laboratories is a US-based pharmaceutical company dedicated to ident
'/>"/>

SOURCE Forest Laboratories, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure as Long-Term Monotherapy and in Combination Therapy
2. Rapid Whole Blood Testing for Infectious Mononucleosis Antibodies
3. Blood Gas Analysis: The Pros and Cons of Point-Of-Care Testing
4. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
5. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
6. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
7. Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur
8. Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
9. Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
10. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
11. NCI Researchers Discover Genes That Are Turned on at High Levels in Tumor-associated Blood Vessels of Mice and Humans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... August 3, 2015 Shire ... today that it has acquired New ... for $300 million. With the acquisition, Shire acquires ... combining 0.6% povidone iodine (PVP-I) and 0.1% dexamethasone), ... of infectious conjunctivitis, an ocular surface condition commonly ...
(Date:8/2/2015)... , Aug. 3, 2015  Lexicon Pharmaceuticals, ... the pivotal TELESTAR Phase 3 clinical trial met ... telotristat etiprate in treating cancer patients with carcinoid ... current standard of care. Telotristat etiprate was discovered ... technology, and is the company,s first discovery to ...
(Date:7/31/2015)... -- More than 1,500 substance abuse prevention and treatment ... Indianapolis Aug. 2-6 for Community Anti-Drug ... . The week-long training, held at the JW Marriott, ... nation,s biggest public health challenges – youth drug use. ... one-of-a-kind intensive training opportunity, offering more than 70 half-day ...
Breaking Medicine Technology:Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 2Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 3Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 4Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 5Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 6Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 2Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 3Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 4Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 5Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 6Community Leaders From Across The Country Head To Indianapolis For CADCA 2015 Mid-Year Training Institute Aug. 2-6 2
... Medical AB ( http://www.omxgroup.com, OMX: DIAM B; ... http://www.otcqx.com, OTC: ... B)(OTC: DMYDY)announced today that the Swedish Medical Products,Agency (MPA) has ... therapeutic diabetes vaccine Diamyd(R)., (Logo: http://www.newscom.com/cgi-bin/prnh/20080314/297194 ), ...
... Onset with SYMBICORT with Improved Lung Function within ... ... WILMINGTON, Del., March 18 Data from a new,study demonstrated ... greater,and faster bronchodilatory effects, or opening of the airways, compared,with ...
Cached Medicine Technology:Diamyd(R) Diabetes Vaccine Receives Approval to Start Phase III Trials in Europe 2Study Compares Bronchodilatory Effects of SYMBICORT(R) and Advair in Adults With Asthma 2Study Compares Bronchodilatory Effects of SYMBICORT(R) and Advair in Adults With Asthma 3Study Compares Bronchodilatory Effects of SYMBICORT(R) and Advair in Adults With Asthma 4
(Date:8/3/2015)... Pass, OR (PRWEB) , ... August 03, 2015 ... ... Northeast California’s Modoc National Forest, to Ahjumawi Lava Springs, California’s northernmost and among ... of California’s largest untapped ground water aquifers, whose main outflow is at Ahjumawi ...
(Date:8/3/2015)... ... August 03, 2015 , ... From 2006-2017 the number ... according to market research compiled for the National Association of Dental Laboratories ( ... Labor, Bureau of Labor Statistics. As the number of dental laboratories decreases, dentists ...
(Date:8/3/2015)... ... 2015 , ... Constantin Vasilica, 48 from Romania wanted to have an alternative ... many years of suffering and using medications with strong side effects. This had already ... extra time off or wait longer hours in the waiting rooms. Instead, he went ...
(Date:8/3/2015)... ... 03, 2015 , ... The American Institute of Architects ... to collaborate across a wide range of initiatives ranging from code development and ... , “Our combined membership, consisting of practicing design professionals, code officials, and the ...
(Date:8/2/2015)... ... August 03, 2015 , ... A new Phase I research study is ... study is led by Kenneth G. Lucas, M.D. , chief of the division ... with colleagues at Kosair Children’s Hospital and in the UofL Department ...
Breaking Medicine News(10 mins):Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 2Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 3Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 4Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 2Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 3Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 2Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 3Health News:Architects, International Code Council Ink Five-Year Collaborative Agreement 2Health News:Architects, International Code Council Ink Five-Year Collaborative Agreement 3Health News:UofL Physicians Conducting Vaccine Trial for Children with Relapsed Tumors at Kosair Children’s Hospital 2
... Exposition Park LOS ANGELES, ... March of Dimes premier fundraising event that benefits all babies--those ... thrive. 11,000 walkers are expected at this largest March for ... Exposition Park, at the corner of S. Figueroa and 39th ...
... associations representing the state,s 114 hospitals have reached a ... 2010.Among other principles, the groups urged the state to ... agreed on a minimum floor that all hospitals should ... shared today with members of the state Legislature by ...
... Saturday, April 25 from 9 a.m. until noon, ... (NAMI-OC) will bring together speakers, agencies and service ... Front Line conferences provide important information on PTSD ... and suicide prevention. The conference is designed not ...
... The National Medical Association (NMA), the nation,s premier ... funding in the amount of $120,000 from the ... of a three-year grant commitment, designed "to promote ... sustaining collaboration among partner organizations."Partner organizations for this ...
... favors people in urban areas , , TUESDAY, April 21 (HealthDay ... or remote areas are not less likely to get a ... finds. , Researchers analyzed U.S. data on 699,751 adults ... list between 1995 and 2007. After about two years on ...
... Patients who drank before diagnosis had reduced risk of ... (HealthDay News) -- Patients with non-Hodgkin lymphoma who drank ... risk of relapse or death, according to a study ... researchers looked at more than 500 women with non-Hodgkin ...
Cached Medicine News:Health News:Farmers Insurance Joins March of Dimes March for Babies April 25, 2009 2Health News:Hospital Groups Stand United on State Budget 2Health News:Hospital Groups Stand United on State Budget 3Health News:Hospital Groups Stand United on State Budget 4Health News:National Medical Association Receives Funding From Kellogg for Training Community Advocates 2Health News:Distance No Bar to Kidney Transplants in Remote Areas 2Health News:Wine May Guard Against Lymphoma Recurrence 2
... Microscope with excellent maneuverability. Konan ... weight maintaining high quality. Easy ... by simply changing the adapter. ... has resulted in a sharp ...
To maintain the conjunctival cul-de-sacs after enucleation or evisceration without hindering lid closure....
With side bite Instrument recommended to catch the polypropylene thread in the nose....
Instrument necessary for insertion of Ritleng Bicanaliculus systems and of Self-Threading Monoka systems....
Medicine Products: